Katarina Le Blanc

List of Publications by Year
in descending order

50 papers	10,240 citations	201674 27 h-index	243625 44 g-index
50 all docs	50 docs citations	50 times ranked	11217 citing authors

#	Article	IF	Citations
1	Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet, The, 2004, 363, 1439-1441.	13.7	2,534
2	Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet, The, 2008, 371, 1579-1586.	13.7	2,474
3	HLA expression and immunologic propertiesof differentiated and undifferentiated mesenchymal stem cells. Experimental Hematology, 2003, 31, 890-896.	0.4	1,510
4	Multipotent mesenchymal stromal cells and the innate immune system. Nature Reviews Immunology, 2012, 12, 383-396.	22.7	811
5	Immunobiology of Human Mesenchymal Stem Cells and Future Use in Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2005, 11, 321-334.	2.0	429
6	Fetal Mesenchymal Stem-Cell Engraftment in Bone after In Utero Transplantation in a Patient with Severe Osteogenesis Imperfecta. Transplantation, 2005, 79, 1607-1614.	1.0	397
7	CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood, 2014, 124, 750-760.	1.4	206
8	Mesenchymal stromal cells and the innate immune response. Immunology Letters, 2015, 168, 140-146.	2.5	204
9	Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Current Opinion in Immunology, 2006, 18, 586-591.	5.5	202
10	In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome. Stem Cells Translational Medicine, 2015, 4, 1199-1213.	3.3	131
11	Challenges for mesenchymal stromal cell therapies. Science Translational Medicine, 2019, 11, .	12.4	126
12	Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy. Cell Stem Cell, 2021, 28, 1708-1725.	11.1	114
13	Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma. Clinical Cancer Research, 2016, 22, 3849-3859.	7.0	109
14	Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies. Biology of Blood and Marrow Transplantation, 2009, 15, 1108-1115.	2.0	100
15	MSCsâ€"cells with many sides. Cytotherapy, 2018, 20, 273-278.	0.7	91
16	Stromal cellâ€"mediated glycolytic switch in CLL cells involves Notch-c-Myc signaling. Blood, 2015, 125, 3432-3436.	1.4	76
17	A low body mass index is correlated with poor survival after allogeneic stem cell transplantation. Haematologica, 2003, 88, 1044-52.	3.5	62
18	Do ABO Blood Group Antigens Hamper the Therapeutic Efficacy of Mesenchymal Stromal Cells?. PLoS ONE, 2014, 9, e85040.	2.5	61

#	Article	IF	Citations
19	Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 2365-2370.	2.0	61
20	A Comparison of Nonmyeloablative and Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation. Transplantation, 2004, 78, 1014-1020.	1.0	59
21	Generation of Immunosuppressive Mesenchymal Stem Cells in Allogeneic Human Serum. Transplantation, 2007, 84, 1055-1059.	1.0	57
22	Type 1 Diabetes Mellitus Donor Mesenchymal Stromal Cells Exhibit Comparable Potency to Healthy Controls In Vitro. Stem Cells Translational Medicine, 2016, 5, 1485-1495.	3.3	51
23	Defined serum-free media for in vitro expansion of adipose-derived mesenchymal stem cells. Cytotherapy, 2014, 16, 915-926.	0.7	48
24	MSC from fetal and adult lungs possess lung-specific properties compared to bone marrow-derived MSC. Scientific Reports, 2016, 6, 29160.	3.3	43
25	Mesenchymal Stromal Cells Disrupt mTOR-Signaling and Aerobic Glycolysis During T-Cell Activation. Stem Cells, 2016, 34, 516-521.	3.2	39
26	Phenotypic and functional alterations of myeloidâ€derived suppressor cells during the disease course of multiple sclerosis. Immunology and Cell Biology, 2018, 96, 820-830.	2.3	38
27	Persistence of Human Parvovirus B19 in Multipotent Mesenchymal Stromal Cells Expressing the Erythrocyte P Antigen: Implications for Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 1172-1179.	2.0	31
28	Heparinization of cell surfaces with short peptide-conjugated PEG-lipid regulates thromboinflammation in transplantation of human MSCs and hepatocytes. Acta Biomaterialia, 2016, 35, 194-205.	8.3	24
29	Use of mesenchymal stem cells for the prevention of immune complications of hematopoietic stem cell transplantation. Haematologica, 2005, 90, 438.	3.5	21
30	Wnt/Î²-Catenin Stimulation and Laminins Support Cardiovascular Cell Progenitor Expansion from Human Fetal Cardiac Mesenchymal Stromal Cells. Stem Cell Reports, 2016, 6, 607-617.	4.8	20
31	Short and Long Term Clinical and Immunologic Follow up after Bone Marrow Mesenchymal Stromal Cell Therapy in Progressive Multiple Sclerosisâ€"A Phase I Study. Journal of Clinical Medicine, 2019, 8, 2102.	2.4	20
32	Consensus International Council for Commonality in Blood Banking Automationâ€"International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells. Cytotherapy, 2021, 23, 1060-1063.	0.7	15
33	Myeloid-derived suppressor cells in allogeneic hematopoietic stem cell transplantation. OncoImmunology, 2013, 2, e25009.	4.6	13
34	MSCs: Scientific Support for Multiple Therapies. Stem Cells International, 2015, 2015, 1-2.	2.5	12
35	Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based Decisions. Biology of Blood and Marrow Transplantation, 2017, 23, 677-683.	2.0	12
36	Five-Year Follow-up after Mesenchymal Stromal Cellâ€"based Treatment of Severe Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1051-1055.	5.6	9

#	Article	IF	Citations
37	Mesenchymal Stem Cells for Treatment of Severe Acute Graft-Versus-Host Disease.. Blood, 2006, 108, 5304-5304.	1.4	8
38	Commentary: Role of Mesenchymal Stromal Cellâ€“Mediated Crosstalk with Macrophages in Graft-versus-Host Disease and Tissue Repair. Biology of Blood and Marrow Transplantation, 2017, 23, 861-862.	2.0	7
39	Mesenchymal Stem Cells for Treatment of Severe Acute Graft-Versus-Host Disease.. Blood, 2006, 108, 2918-2918.	1.4	4
40	Enhanced oral healing following local mesenchymal stromal cell therapy. Oral Oncology, 2015, 51, e97-e99.	1.5	3
41	Mesenchymal Stem Cells for Treatment of Severe Acute and Extensive Chronic Graft-Versus-Host Disease.. Blood, 2005, 106, 143-143.	1.4	3
42	Diversity of respiratory parameters and metabolic adaptation to low oxygen tension in mesenchymal stromal cells. Metabolism Open, 2022, 13, 100167.	2.9	2
43	Immunohistopathology of oral mucosal chronic graftâ€versusâ€host disease severity and duration. Oral Diseases, 2023, 29, 3346-3359.	3.0	2
44	Stromal progenitor cell modulation by thalidomide in the treatment of oral chronic graft-versus-host disease. Cytotherapy, 2018, 20, 755-758.	0.7	1
45	Immune Escape and Suppression by Human Mesenchymal Stem Cells. , 2006, , 233-245.		0
46	Transplantation of Haplo-Identical Bone Marrow-Derived Mesenchymal Stem Cells Together with Hematopoietic Stem Cells To Promote Engraftment in Children. A Phase I/II Multicenter Study.. Blood, 2005, 106, 2911-2911.	1.4	0
47	HLA Mismatched MSC Suppress T Lymphocyte Allo responses in Vitro and Do Not Induce Immunological Memory in Recipients of MSC Infusion. Blood, 2008, 112, 4740-4740.	1.4	0
48	Human Mesenchymal Stem Cells Elicit Complement Activation in Human Blood.. Blood, 2009, 114, 4580-4580.	1.4	0
49	Phenotypic and Functional Alterations of Bone Marrow Mesenchymal Stem and Progenitor Cells in Chronic Myeloid Leukemia. Blood, 2015, 126, 2398-2398.	1.4	0
50	Manufacturing of Mesenchymal Stromal Cells for the Treatment of Graft-Versus-Host Disease: A Survey within the European Society of Blood and Marrow Transplantation. Blood, 2016, 128, 3374-3374.	1.4	0